Over the last two decades blood transfusion practices, once considered to offer clinical benefits with a relatively low-risk, began to come under systematic scrutiny. Ongoing clinical research showed that restrictive strategies for red-cell transfusion may be more beneficial. More recent studies show that overall decreasing transfusion requirements do not necessarily increasing adverse outcomes and, in the case of certain pediatric surgeries, may benefit stable, critically ill children.…Continue
Added by Editorial Team on September 23, 2013 at 9:30am — No Comments
Findings presented at the European Respiratory Society (ERS) Annual Congress, being held in Barcelona, Spain (September 7 - 11, 2013), shows that collecting samples of exhaled breath from people at a high risk of lung cancer could be a cheap and non-invasive method of diagnosing the disease, according to new research.
Current tests for lung cancer include blood and urine tests, followed by CT scans and chest…Continue
Added by Peter Hofland, PhD on September 9, 2013 at 10:00pm — No Comments
The multifunctional cytokine Interleukin-7 (IL-7) is an important immune messenger protein which ensures that a sufficient number of T-cells are present in our body for immune defense. IL-7 is mainly produced by non-hematopoietic cells, including stromal cells in the bone marrow and thymus. The hematopoietic growth factor is also produced by keratinocytes, fetal liver, adult liver, dendritic cells, hepatocytes, neurons, and epithelial cells but not by normal lymphocytes.
Added by Editorial Team on August 26, 2013 at 7:30am — No Comments
The Food and Drug Administration has granted an Orphan drug designation to EPZ-5676, a small molecule inhibitor of DOT1L for the treatment of acute leukemias in which the MLL (ALL1) gene, located at 11q23, is rearranged due to a chromosomal translocation (MLL-r).
Due to the translocation, DOT1L is recruited to specific locations in the chromosome where it would not normally be present. As a result, DOT1L causes inappropriate methylation at these locations, which results in…Continue
Added by Editorial Team on August 16, 2013 at 5:30am — No Comments
Researchers at Weill Cornell Medical College in New York have discovered how an experimental drug is capable of completely eradicating human lymphoma in mice after just five doses. The study sets the stage for testing the drug in clinical trials of diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, itself the seventh most frequently diagnosed cancer in the U.S.
Added by Editorial Team on August 1, 2013 at 6:00pm — No Comments
A study published in the July 17, 2013 issue of Journal of the National Cancer Institute (JNCI)  shows that the addition of the erythropoiesis-stimulating agent (ESA) epoetin alfa (Epogen®, Amgen; Eprex®, Janssen-Cilag; Procrit®, Janssen Products) to the chemotherapy regimen in…Continue
Added by Editorial Team on July 17, 2013 at 5:30pm — No Comments
Earlier this week Swiss-based oncology drug development company ADC Therapeutics Sarl and Danish Genmab A/S agreed to develop a new antibody-drug conjugate (ADC) combining HuMax®-TAC antibody and a PBD-based warhead and linker technology. The companies have been conducting in vitro and in vivo studies since 2012 to investigate different warhead and linker combinations with…Continue
Added by Editorial Team on June 18, 2013 at 7:00am — No Comments
Data presented at the 18th Annual Congress of the European Hematology Association (EHA) being held in Stockholm, Sweden, June 13 - 16, 2013, of two separate Phase II studies suggest that ibrutinib (PCI-32765), an investigational oral Bruton's tyrosine kinase (BTK) inhibitor, shows efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL).…Continue
Added by Editorial Team on June 16, 2013 at 6:00pm — No Comments
Added by Editorial Team on May 5, 2013 at 9:00pm — No Comments
To improve the prognosis of patients with pancreatic cancer, a more accurate serum diagnostic method is required. Now researchers have developed a new diagnostic test that uses a scientific technique known as metabolomic analysis that may be a safe and easy screening method.The researchers believe that this new test may improve the prognosis, offering patients with pancreatic cancer a real survival advantage through earlier detection.
According to data from the…Continue
Added by Peter Hofland, PhD on March 29, 2013 at 9:30am — No Comments
Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody specific for CD44 (RG7356) that targets and directly kills chronic lymphocytic leukemia (CLL) cells. The adhesion molecule CD44 is a transmembrane glycoprotein that is overexpressed in a number of solid tumor and hematologic malignancies and is associated with a poor prognosis. The findings, published in…Continue
Added by Peter Hofland, PhD on March 25, 2013 at 6:30pm — No Comments
Earlier today the first patient has been enrolled in the pivotal pediatric phase III study to evaluate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) in previously treated children (up to age 11 years). The study site for this first enrollment is the Czech Republic.
Hemophilia is an inherited bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles…Continue
Added by Peter Hofland, PhD on January 31, 2013 at 8:30pm — No Comments
Deferasirox (Exjade®, Novartis) is the first oral treatment approved in the EU for chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndromes. A pivotal placebo-controlled study data shows that the drug significantly decreases iron burden in NTDT patients versus placebo, with similar overall adverse event rate
Worldwide, at least…Continue
Added by Editorial Team on December 21, 2012 at 5:00pm — No Comments
A glass plate with a nanoscale roughness could be a simple way for scientists to capture and study the circulating tumor cells (CTC) that carry cancer around the body through the bloodstream (illustration). Engineering and medical researchers at the …Continue
Added by Editorial Team on December 12, 2012 at 6:30pm — No Comments
Clinical and pre-clinical data presented at the 54th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA, December 8 - 11, 2012, demonstrates that the investigational agent PCI-32765 (ibrutinib; Pharmacyclics®) offers prolonged progression free survival with a manageable and predictable safety profile in high unmet need indications in relapsed and refractory, high risk, advanced CLL/SLL and MCL patients and…Continue
Added by Peter Hofland, PhD on December 11, 2012 at 2:30pm — No Comments
Researchers conducting a preclinical study in mice successfully used targeted molecular therapy to block mostly untreatable nerve tumors that develop in people with the genetic disorder Neurofibromatosis 1 (NF1). Scientists from Cincinnati Children's Hospital Medical Center report their findings online December 10, 2012 in the Journal of Clinical…Continue
Added by Editorial Team on December 10, 2012 at 8:30am — No Comments
Results of the Phase III AMPLIFY-EXT trial (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXTended Treatment) evaluating the prevention of recurrent venous thromboembolism (VTE) in 2,486 patients who had already completed 6 to 12 months of anticoagulation treatment for VTE, including deep vein thrombosis (DVT) or pulmonary embolism (PE) shows that apixaban (Eliquiq®, Bristol-Myers…Continue
Added by Peter Hofland, PhD on December 8, 2012 at 2:30pm — No Comments
The U.S. Food and Drug Administration (FDA) has approved a new indication for eltrombopag (Promacta®/Revolade®; GSK/GlaxoSmithKline), a thrombopoietin receptor agonist. The new indication approves eltrombopag for the treatment of thrombocytopenia (low blood platelet counts) in patients…Continue
Added by Editorial Team on November 19, 2012 at 5:00pm — No Comments
Research led by a team of researchers working at the St. Jude Children’s Research Hospital in Memphis, TN and the Washington University Pediatric Cancer Genome Project have identified a fusion gene responsible for nearly 30% of a rare subtype of childhood leukemia with an extremely poor prognosis.
This unique finding offers the first evidence of a mistake that gives rise to a significant percentage of acute megakaryoblastic…Continue
Added by Editorial Team on November 12, 2012 at 9:00pm — No Comments
New findings that highlight the challenges of managing thromboembolic events in patients being treated for cancer were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna (September 28 - October 2, 2012).
Venous thromboembolism causes symptoms in about 3 to 4% of cancer patients whose chemotherapy drugs are delivered via a central venous catheter, commented Fausto Roila, M.D. from Medical Oncology Department, Terni,…Continue
Added by Peter Hofland, PhD on October 1, 2012 at 9:30pm — No Comments